<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930864</url>
  </required_header>
  <id_info>
    <org_study_id>MetIri</org_study_id>
    <nct_id>NCT01930864</nct_id>
  </id_info>
  <brief_title>Metformin Plus Irinotecan for Refractory Colorectal Cancer</brief_title>
  <official_title>Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to
      irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine,
      irinotecan and anti-EGFr antibody if Kras wild type.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Non-Progression at week 12th of treatment</measure>
    <time_frame>12th week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12th week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12th week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of toxicity according to CTC 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Metfomin + irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin up to 2500mg/d</description>
    <arm_group_label>Metfomin + irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 350 mg/m² IV q21d</description>
    <arm_group_label>Metfomin + irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Biopsy-proven colorectal adenocarcinoma

          -  Ineligibility for curative intent therapy, e.g., surgery or radiation

          -  Disease progression after oxaliplatin (either adjuvant or palliative),
             fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a
             anti-EGFR therapy

          -  Assessable disease according to RECIST v1.1

        Exclusion Criteria:

          -  known hypersensitivity to metformin or irinotecan

          -  SNC metastasis

          -  Acute or chronic severe infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joao Paulo SN Lima, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joao Paulo SN Lima, MD</last_name>
    <phone>551733216600</phone>
    <phone_ext>7128</phone_ext>
    <email>jpsnlima@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arinilda C Bragagnoli, MD</last_name>
    <phone>551733216600</phone>
    <phone_ext>6829</phone_ext>
    <email>aryscampos@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao Paulo SN Lima, MD</last_name>
      <phone>551733216600</phone>
      <phone_ext>7128</phone_ext>
      <email>joaopaulo.oncologia@hcancerbarretos.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Arinilda C Bragagnoli, MD</last_name>
      <phone>551733216600</phone>
      <phone_ext>6829</phone_ext>
      <email>aryscampos@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Joao Paulo SN Lima, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of Campinas</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>1300000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lígia T Macedo, MD</last_name>
      <email>ligaimed@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ligia T Macedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
